NEU 15.1% $16.57 neuren pharmaceuticals limited

Rett Syndrome Study - new site, page-12

  1. 2,136 Posts.
    lightbulb Created with Sketch. 61
    I assume it is another Phase 2a study based on -

    "The purpose of the study is to look at the safety and tolerability of trofinetide in children and adolescents with Rett syndrome. The study will also investigate the effectiveness of trofinetide during treatment."

    From rettstudy.com
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$16.57
Change
2.170(15.1%)
Mkt cap ! $2.117B
Open High Low Value Volume
$14.85 $16.67 $14.60 $24.77M 1.544M

Buyers (Bids)

No. Vol. Price($)
1 1500 $16.52
 

Sellers (Offers)

Price($) Vol. No.
$16.57 1717 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.